Back to search
CAH - 21-Hydroxylase Deficiency
Clinical trial pipeline · Data from ClinicalTrials.gov
See which CAH - 21-Hydroxylase Deficiency trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which CAH - 21-Hydroxylase Deficiency trials you may qualify forThis study will evaluate and gather information in patients with genetic causes of too much androgen (male-like hormone) in order to better understand the effec…
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participant…
The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.
Congenital adrenal hyperplasia (CAH) is a genetic disease with autosomal recessive transmission, which is defined by a deficiency of one of the steroidogenesis…
The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \<2 years of age with congenital adren…
Neonatal salt loss can be caused not only by infections but also by rare endocrine disorders that resemble 21-hydroxylase deficiency but are not detected by neo…
The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.
An investigation of the safety and efficacy of tildacerfont in participants with CAH.
This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal…